Market revenue in 2021 | USD 4.0 million |
Market revenue in 2032 | USD 23.1 million |
Growth rate | 17.2% (CAGR from 2021 to 2032) |
Largest segment | Chronic immunomodulators |
Fastest growing segment | Monoclonal Antibodies |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Chronic immunomodulators was the largest segment with a revenue share of 32.5% in 2021. Horizon Databook has segmented the South Africa myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
South Africa has the highest HIV prevalence in the world. According to a study published by Frontiers in Neurology, in August 2020, individuals suffering from HIV are at high risk and may develop MG, which is expected to boost the demand for its treatment therapies in South Africa.
In addition, according to a study published by Journal of Medicine, in May 2021, MG can affect individuals of all races and ethnic backgrounds; however, it is slightly more prevalent in individuals of African ancestry.
Increasing public-private initiatives for raising awareness about rare diseases, including MG, and improving access to high-grade diagnosis & treatment are further expected to support market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into South Africa myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account